Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 to $17 per share. | Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.

According to a filing with the Securities and Exchange Commission dated October 20, 2025, Renaissance Capital reported a new stake in Circle Internet Group, purchasing 51,208 shares during the third quarter.

Navan's shares started trading 12% below their initial public offering price on Thursday, as the travel technology company faced choppy market conditions amid a prolonged U.S. government shutdown.

Corporate travel and expense management firm Navan Inc. (NASDAQ: NAVN) burst onto the public markets this week, raising about $923 million in its long-awaited U.S. IPO.

Navan priced its IPO at $25 per share, aiming to raise around $700 million, with shares set to begin trading on Nasdaq. The company has grown through both organic expansion and strategic acquisitions, and plans to continue acquiring companies post-IPO.

Safecure Services IPO witnessed a sharp decline in the grey market premium (GMP) as the offer opened. Safecure Services IPO GMP today was nil. This means that shares traded at par to the issue price of ₹102.

Explore the top IPO stocks to invest in, with expert tips on evaluating new public companies and how to invest to maximize your returns.

British lender Shawbrook is set to float on the London Stock Exchange on Thursday at a valuation of about 1.92 billion pounds ($2.58 billion) after pricing its shares at 3.70 pounds each, in what will be London's biggest initial public offering in two years.

At the upper end of the price band, Peyush Bansal-led company is seeking a valuation of close to ₹70,000 crore. Lenskart IPO is also enjoying a decent grey market premium, signalling investor interest ahead of the launch of the public offer.